Poolbeg Pharma PLC Capital Markets Day (6932G)
November 17 2022 - 2:00AM
UK Regulatory
TIDMPOLB
RNS Number : 6932G
Poolbeg Pharma PLC
17 November 2022
Poolbeg Pharma Plc
Capital Markets Day
17 November 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical stage infectious disease
pharmaceutical company with a unique capital light clinical model,
announces that it will be holding a Capital Markets Day for
analysts and institutional investors on Wednesday 30 November
between 10am - 12:45pm.
The event, which will be chaired by Jeremy Skillington, Chief
Executive Officer, will provide insights into a number of the
Company's growing pipeline of infectious disease vaccines and
treatments and one of its innovative artificial intelligence
programmes which is unlocking the power of human challenge trial
data. In addition, attendees will gain a greater understanding of
how Poolbeg's unique model and business development strategy can
drive growth from the infectious disease market. A networking lunch
will follow at the end of the session.
There will be an opportunity for attendees to take part in a
Q&A with Poolbeg's management team including Ian O'Connell,
Chief Financial Officer and David English, VP of Business
Development as well as a number of guest speakers:
-- Dr Tal Almog of CytoReason, one of Poolbeg's artificial intelligence
partners; a world leader in AI which to date has worked with five
of the world's top ten pharma companies
-- Derek Gilroy, Head of the Centre for Clinical Pharmacology and
Professor of Immunology at University College London and has pioneered
research examining the molecular and biochemical pathways that
regulates the resolution of acute immune reactions
-- Professor Brendan Buckley, co-founder of Minerva Medical, acquired
by IQVIA and Firecrest Clinical, acquired by ICON plc where he
held the position of Chief Medical Officer. Brendan has over thirty
years of experience in clinical research and has published over
150 scientific papers
-- Further speakers will be announced in advance of the event
Analysts, institutional investors and media are welcome to
attend the event in the City of London. Due to restrictions on
numbers, it will not be possible for all interested parties to
attend in-person. However, a live webcast will be available for
retail investors and others to view the presentations here .
To register your interest to attend the in-person event, please
RSVP to poolbeg@instinctif.com .
A recording of the presentation will be made available on the
Company's website after the event here .
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, Charlie Beeson
Nigel Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, Tim poolbeg@instinctif.com
Field
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease
pharmaceutical company, with a capital light clinical model which
aims to develop multiple products faster and more cost effectively
than the conventional biotech model. The Company, headquartered in
London, is led by a team with a track record of creation and
delivery of shareholder value and aspires to become a "one-stop
shop" for Big Pharma seeking mid-stage products to license or
acquire.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from hVIVO plc (formerly named Open
Orphan plc), an industry leading infectious disease and human
challenge trials business, Poolbeg has access to knowledge,
experience, and clinical data from over 20 years of human challenge
trials. The Company is using these insights to acquire new assets
as well as reposition clinical stage products, reducing spend and
risk. Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza (POLB 001) which has
commenced its LPS human challenge trial with initial results
expected by year end 2022; a first-in-class, intranasally
administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis
(POLB 003). The Company is also developing an oral vaccine delivery
platform and is progressing two artificial intelligence (AI)
programmes to accelerate the power of its human challenge model
data and biobank, with outputs from the first programme expected by
year end 2022.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZMMMMVDGZZZ
(END) Dow Jones Newswires
November 17, 2022 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024